申联生物(688098) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥115,969,622.58, a decrease of 4.89% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2025 was ¥13,147,752.50, down 35.50% year-on-year[3]. - The total profit for the year-to-date period was ¥14,915,913.37, reflecting a decline of 16.88%[3]. - Total revenue for the first three quarters of 2025 was CNY 237,694,760.86, a decrease of 4.5% compared to CNY 248,302,819.25 in the same period of 2024[18]. - Net profit for the first three quarters of 2025 was a loss of CNY 3,022,872.00, an improvement from a loss of CNY 17,020,443.48 in the same period of 2024[20]. - The company’s total comprehensive loss for the period was CNY 3,022,872.00, compared to a loss of CNY 17,020,443.48 in the previous year[20]. Research and Development - Research and development expenses totaled ¥14,123,079.26 in Q3 2025, a decrease of 12.64% compared to the previous year[4]. - The ratio of R&D expenses to operating revenue was 12.18%, down 1.08 percentage points year-on-year[4]. - Research and development expenses were CNY 31,220,699.23, down from CNY 37,754,809.62, a reduction of 17.5%[18]. - The company is actively developing multi-valent vaccines and exploring a dual business model of "innovative drugs + animal health" to drive growth[9]. Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -¥18,106,094.12 for the year-to-date period, a decline of 245.16%[4]. - The net cash flow from operating activities was -$18.1 million, a decrease from $12.5 million in the previous period[22]. - The cash outflow from operating activities totaled $177.9 million, compared to $209.2 million in the prior year[22]. - Cash received from sales of goods and services was CNY 146,597,121.05, down from CNY 208,274,801.53, representing a decrease of 29.6%[21]. - The ending cash and cash equivalents balance was $73.96 million, down from $98.05 million year-over-year[22]. - The company experienced a net decrease in cash and cash equivalents of $37.2 million, contrasting with an increase of $53.2 million in the previous period[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,560,336,881.57, an increase of 0.40% from the end of the previous year[4]. - Total assets as of September 30, 2025, amounted to RMB 1,560,336,881.57, compared to RMB 1,554,117,949.14 as of December 31, 2024, showing a slight increase[14]. - Total liabilities increased to CNY 139,417,180.20 from CNY 128,495,487.08, an increase of 7.2%[17]. - Total equity attributable to shareholders decreased slightly to CNY 1,409,893,375.64 from CNY 1,411,295,212.77[16]. Shareholder Information - The company reported a total of 12,388 common shareholders at the end of the reporting period[11]. - The largest shareholder, Yang Yufang, holds 90,063,197 shares, representing 21.93% of total shares[11]. - The second-largest shareholder, UNITED BIOMEDICAL, INC., holds 43,199,898 shares, accounting for 10.52%[11]. - The combined shareholding of the top four shareholders is 35.82%, indicating a significant concentration of ownership[12]. - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[13]. Operating Costs - Total operating costs decreased to CNY 235,297,261.25 from CNY 259,262,501.74, reflecting a reduction of 9.2%[18]. Other Income - The company reported a significant increase in other income to CNY 3,773,232.91 from CNY 2,848,837.55, an increase of 32.4%[19]. Accounting Standards - The company will not apply new accounting standards starting from 2025[23].